{
  "meta": {
    "title": "72_Sle_Anti_Phospholipid_Syndrome",
    "url": "https://brainandscalpel.vercel.app/72-sle-anti-phospholipid-syndrome-07504a0f.html",
    "scrapedAt": "2025-11-30T06:57:38.454Z"
  },
  "questions": [
    {
      "id": 96078,
      "choices": [
        {
          "id": 245891,
          "text": "SLE"
        },
        {
          "id": 245892,
          "text": "Rheumatoid arthritis"
        },
        {
          "id": 245893,
          "text": "Seronegative arthropathy"
        },
        {
          "id": 245894,
          "text": "MCTD"
        }
      ],
      "text": "A 30-year-old female presents with alopecia to a dermatology clinic. She also has pain in the joints for the past 6 months for which she is on NSAIDS. However, there is no deformity. She has no hematuria or dysuria. Urine analysis reveals 3+ proteinuria with granular cast. ANA by ELISA was positive. RA factor was negative. What is the most likely diagnosis:",
      "unique_key": "Q7590000",
      "question_audio": null,
      "question_video": null,
      "map_id": 34909476,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Systemic Lupus Erythematosus (SLE). SLE is an autoimmune disorder that can involve multiple organ systems. The patient presents with alopecia, joint pain, and significant proteinuria (3+ on urine analysis) with granular casts, which strongly suggests kidney involvement, specifically lupus nephritis, a common complication of SLE. The positive ANA (antinuclear antibody) test is highly sensitive for SLE, further supporting the diagnosis. Although NSAIDs may provide symptomatic relief for joint pain, they do not treat the underlying disease. The absence of joint deformities aligns with SLE-related arthritis, which is non-erosive, unlike rheumatoid arthritis. The combination of clinical features and laboratory findings makes SLE the most likely diagnosis. Why the Other Options Are Incorrect: B) Rheumatoid Arthritis (RA): RA typically presents with symmetrical joint pain, stiffness (especially in the morning), and progressive joint deformities due to erosive arthritis. Although the patient has joint pain, the lack of deformity and a negative RA factor argue against this diagnosis. Additionally, RA does not typically cause significant proteinuria or renal involvement, which are seen in this patient. C) Seronegative Arthropathy: Seronegative spondyloarthropathies (e.g., ankylosing spondylitis, psoriatic arthritis) usually present with joint involvement, particularly of the axial skeleton, sacroiliac joints, or large joints. They are not commonly associated with alopecia, positive ANA, or significant renal pathology, such as proteinuria or granular casts. The patient’s presentation does not align with the typical features of this group of diseases. D) Mixed Connective Tissue Disease (MCTD): MCTD shares overlapping features of SLE, systemic sclerosis, and polymyositis, and typically presents with Raynaud's phenomenon, swollen fingers, and high titers of anti-U1 RNP antibodies. While MCTD can present with positive ANA and joint pain, the absence of these hallmark features and specific anti-U1 RNP antibody results makes MCTD less likely than SLE in this case.",
      "correct_choice_id": 245891,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37010081698838585/37010081698838585.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37010081698838585/37010081698838585.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96079,
      "choices": [
        {
          "id": 245895,
          "text": "ANA"
        },
        {
          "id": 245896,
          "text": "Anti-dsDNA antibody"
        },
        {
          "id": 245897,
          "text": "Anti-phospholipid antibody"
        },
        {
          "id": 245898,
          "text": "Anti-Ro antibody"
        }
      ],
      "text": "Which of the following have been included in the immunological criteria for SLE (SLICC) Except:",
      "unique_key": "Q7190179",
      "question_audio": null,
      "question_video": null,
      "map_id": 34844249,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Anti-Ro antibody. The Systemic Lupus International Collaborating Clinics (SLICC) criteria for diagnosing SLE include specific immunological markers. These criteria are focused on antibodies that are directly associated with lupus pathogenesis and clinical relevance. Anti-Ro antibodies are not specifically included in the immunological criteria of the SLICC classification for SLE, though they are relevant in related conditions like Sjögren’s syndrome or subacute cutaneous lupus erythematosus. The inclusion criteria emphasize markers with stronger diagnostic specificity for SLE. Why the Other Options Are Correct: A) ANA (Antinuclear Antibody): ANA is included in the SLICC immunological criteria as it is highly sensitive for SLE, with almost all patients testing positive at some point in their disease course. While ANA alone is not specific to SLE, its presence is a hallmark of autoimmune diseases, including lupus. B) Anti-dsDNA Antibody: Anti-dsDNA antibody is highly specific to SLE and is a key immunological criterion in the SLICC classification. It is closely associated with lupus nephritis and disease activity. Its specificity makes it an important diagnostic and monitoring tool for SLE. C) Anti-Phospholipid Antibody: Anti-phospholipid antibodies (e.g., lupus anticoagulant, anticardiolipin antibodies) are included in the SLICC criteria because of their association with the anti-phospholipid syndrome (APS), which can occur as part of SLE. These antibodies contribute to an increased risk of thrombosis and pregnancy complications in lupus patients, making their detection clinically significant. Why the Correct Answer Is Incorrect: D) Anti-Ro Antibody: Although anti-Ro antibodies are associated with certain SLE manifestations (e.g., subacute cutaneous lupus, neonatal lupus, and photosensitivity), they are not explicitly included in the SLICC immunological criteria. Their presence is more characteristic of conditions such as Sjögren’s syndrome. Therefore, while anti-Ro antibodies may aid in clinical evaluation, they are not part of the specific SLICC immunological markers used to classify SLE.",
      "correct_choice_id": 245898,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42589251698838599/42589251698838599.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42589251698838599/42589251698838599.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96080,
      "choices": [
        {
          "id": 245899,
          "text": "Captopril"
        },
        {
          "id": 245900,
          "text": "Simvastatin"
        },
        {
          "id": 245901,
          "text": "Interferons"
        },
        {
          "id": 245902,
          "text": "Tacrolimus"
        }
      ],
      "text": "All of the following are known to cause drug induced Lupus except:",
      "unique_key": "Q7600772",
      "question_audio": null,
      "question_video": null,
      "map_id": 34465484,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Tacrolimus. Tacrolimus is an immunosuppressive agent primarily used in organ transplantation and autoimmune diseases to prevent rejection or manage immune-mediated conditions. It modulates T-cell activation and is not known to cause drug-induced lupus. Instead, it is sometimes used as a treatment option in autoimmune diseases, including lupus nephritis. Its mechanism of action and immunosuppressive properties make it highly unlikely to induce lupus-like symptoms. Why the Other Options Are Correct: A) Captopril: Captopril, an angiotensin-converting enzyme (ACE) inhibitor, has been associated with drug-induced lupus erythematosus (DILE). The mechanism involves its ability to trigger autoantibody formation through immune modulation, though this is a rare adverse effect. B) Simvastatin: Simvastatin, a lipid-lowering statin, has been implicated in rare cases of drug-induced lupus. Statins are generally considered safe but can occasionally cause autoimmune phenomena, including lupus-like syndromes, likely through immune system dysregulation. C) Interferons: Interferons, particularly interferon-alpha, are known to induce lupus-like syndromes. They promote immune activation and autoantibody production, contributing to lupus pathogenesis in susceptible individuals. These drugs are strongly associated with drug-induced lupus, especially in patients receiving them for chronic viral infections or cancers. Why the Correct Answer Is Incorrect: D) Tacrolimus: Tacrolimus does not cause drug-induced lupus. On the contrary, it is often used to treat autoimmune conditions, including lupus nephritis, due to its immunosuppressive effects. It reduces immune activation and inflammation, making it therapeutically beneficial rather than a trigger for lupus.",
      "correct_choice_id": 245902,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21119001698838611/21119001698838611.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/21119001698838611/21119001698838611.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96081,
      "choices": [
        {
          "id": 245903,
          "text": "Anti- Neuronal antibody"
        },
        {
          "id": 245904,
          "text": "Anti-Ribosomal P antibody"
        },
        {
          "id": 245905,
          "text": "Anti- dsDNA"
        },
        {
          "id": 245906,
          "text": "Anti-phospholipid antibody"
        }
      ],
      "text": "A 22-year female diagnosed as a case of SLE is on immunosuppression since the last 8 months. She is brought to the emergency department in altered sensorium with h/o convulsion. Which is/are the antibody associated with increased risk of above manifestation EXCEPT:",
      "unique_key": "Q7177568",
      "question_audio": null,
      "question_video": null,
      "map_id": 34999916,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) This is not directly associated with non-thrombotic neuropsychiatric manifestations like seizures and altered sensorium. Anti-phospholipid antibodies (aPL) are primarily associated with vascular complications, such as stroke, DVT, and pregnancy loss. While they can cause CNS symptoms, it’s usually via thrombosis, not by causing neuropsychiatric SLE in the absence of infarction or vascular lesions. So, in a patient with convulsions and altered sensorium (without stroke evidence), aPL is less relevant than the other options. A. Anti-Neuronal antibody Linked to direct autoimmune attack on CNS neurons. Associated with seizures, cognitive dysfunction, and behavioral changes. B. Anti-Ribosomal P antibody One of the strongest markers of neuropsychiatric SLE. Associated with psychosis, seizures, mood disorders. C. Anti-dsDNA antibody Primarily known for lupus nephritis, but high titers may correlate with disease activity, including CNS involvement. Still more relevant than aPL in non-thrombotic NPSLE.",
      "correct_choice_id": 245906,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6017301698838643/6017301698838643.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/6017301698838643/6017301698838643.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96082,
      "choices": [
        {
          "id": 245907,
          "text": "Renal Failure"
        },
        {
          "id": 245908,
          "text": "Heart Failure"
        },
        {
          "id": 245909,
          "text": "Infection"
        },
        {
          "id": 245910,
          "text": "Bleeding"
        }
      ],
      "text": "The most common cause of late mortality in a patient of SLE is:",
      "unique_key": "Q1569470",
      "question_audio": null,
      "question_video": null,
      "map_id": 34815403,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Heart Failure. In patients with systemic lupus erythematosus (SLE), heart failure is a significant cause of late mortality, often related to long-term cardiovascular complications. SLE increases the risk of accelerated atherosclerosis and coronary artery disease due to chronic inflammation, immune dysregulation, and the effects of prolonged glucocorticoid use. Additionally, myocarditis, pericarditis, and valvular diseases may contribute to cardiac dysfunction over time. These cardiac issues culminate in heart failure, which becomes a prominent cause of death in patients with long-standing SLE, especially as survival from earlier complications improves with modern treatments. Why the Other Options Are Incorrect: A) Renal Failure: Renal failure, particularly from lupus nephritis, is a leading cause of early mortality in SLE patients. Advances in the treatment of lupus nephritis, including immunosuppressive therapies, have significantly reduced mortality from renal failure, making it less common as a cause of death in the late stages of the disease. C) Infection: Infections are a leading cause of early to intermediate mortality in SLE, especially in patients on immunosuppressive therapy. While infections remain a concern throughout the disease course, their role in late mortality is less significant compared to long-term cardiovascular complications like heart failure. D) Bleeding: Bleeding is an uncommon cause of death in SLE. When it occurs, it is often due to complications like thrombocytopenia (secondary to immune-mediated destruction or treatment effects) or anticoagulant use for associated antiphospholipid syndrome. However, bleeding is not a significant contributor to late mortality in SLE.",
      "correct_choice_id": 245908,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/68454741698838681/68454741698838681.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/68454741698838681/68454741698838681.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96083,
      "choices": [
        {
          "id": 245911,
          "text": "IV Methylprednisolone"
        },
        {
          "id": 245912,
          "text": "Azathioprine"
        },
        {
          "id": 245913,
          "text": "IV Rituximab"
        },
        {
          "id": 245914,
          "text": "IV Belimumab"
        }
      ],
      "text": "Following drugs are approved for autoimmune crisis in SLE except",
      "unique_key": "Q3584655",
      "question_audio": null,
      "question_video": null,
      "map_id": 34585349,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Azathioprine. Azathioprine is an immunosuppressive drug commonly used in the maintenance therapy of systemic lupus erythematosus (SLE), but it is not approved for autoimmune crises or acute flares of SLE. During an autoimmune crisis or severe flare, more potent immunosuppressive agents such as IV methylprednisolone or biologics like rituximab and belimumab are typically used to quickly control the inflammation. Azathioprine works over a longer period and is not a first-line agent for the acute management of SLE crises. Why the Other Options Are Correct: A) IV Methylprednisolone: IV methylprednisolone is a commonly used treatment in autoimmune crises in SLE. It is a potent corticosteroid that helps reduce inflammation and control acute flares by suppressing the immune system rapidly. This treatment is considered a cornerstone in managing severe SLE manifestations, including nephritis, lupus encephalopathy, or severe skin manifestations. C) IV Rituximab: IV rituximab is a monoclonal antibody that targets CD20 on B cells, which are involved in the autoimmune process in SLE. It is approved for use in SLE, especially for cases that are refractory to traditional therapies. Rituximab can be used in severe flares or autoimmune crises, particularly in cases of lupus nephritis or refractory disease. D) IV Belimumab: IV belimumab is a monoclonal antibody that inhibits BAFF (B-cell activating factor), a cytokine that plays a key role in the survival of B cells. Belimumab is approved for the maintenance therapy of SLE, and it can also be used in the management of acute flares or autoimmune crises when other treatments are ineffective. It is particularly helpful in patients with moderate to severe disease activity.",
      "correct_choice_id": 245912,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3609311698838903/3609311698838903.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/3609311698838903/3609311698838903.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96084,
      "choices": [
        {
          "id": 245915,
          "text": "This is seen in SLE patient"
        },
        {
          "id": 245916,
          "text": "It is papulo-nodular"
        },
        {
          "id": 245917,
          "text": "Painful rash"
        },
        {
          "id": 245918,
          "text": "All are true statements"
        }
      ],
      "text": "The following statements about the skin lesion shown in picture are true except:<p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/course_file_meta/7228638q501medrheu.jpg\" alt=\"Question Image\"></p>",
      "unique_key": "Q5394418",
      "question_audio": null,
      "question_video": null,
      "map_id": 34424710,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Painful rash. The skin lesion described in the question is most likely a lupus erythematosus lesion (specifically discoid lupus erythematosus or acute cutaneous lupus). These lesions are typically not painful, but they may be itchy or sore. Painful rashes are not characteristic of SLE-related skin lesions. Instead, the lesions tend to be asymptomatic or slightly tender. This makes pain not a typical feature of the skin rash seen in SLE. Why the Other Options Are Correct: A) This is seen in SLE patient: SLE (Systemic Lupus Erythematosus) is often associated with various skin manifestations, including malar rashes (butterfly-shaped rash) and discoid lupus lesions, which can be papular and nodular in appearance. These skin lesions are one of the hallmark features of SLE and can appear in a significant number of patients. Thus, it is correct to say that SLE patients often have this type of skin lesion. B) It is papulo-nodular: The skin lesions of SLE can indeed be papulo-nodular in appearance, especially in discoid lupus erythematosus (a chronic skin manifestation of SLE). These lesions are raised, red, and may form scaly plaques or nodules. Papulo-nodular lesions are typical for lupus-related rashes and are a valid description of the skin lesion. D) All are true statements: Since option C is incorrect, option D (\"All are true statements\") is also incorrect. If one statement is false, the answer \"All are true statements\" cannot be correct.",
      "correct_choice_id": 245917,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49637331698838923/49637331698838923.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/49637331698838923/49637331698838923.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96085,
      "choices": [
        {
          "id": 245919,
          "text": "myelitis"
        },
        {
          "id": 245920,
          "text": "neuropathy"
        },
        {
          "id": 245921,
          "text": "convulsion"
        },
        {
          "id": 245922,
          "text": "cognitive impairment"
        }
      ],
      "text": "The most common neurological manifestation in SLE is",
      "unique_key": "Q5192240",
      "question_audio": null,
      "question_video": null,
      "map_id": 34577811,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Cognitive impairment. Cognitive impairment is the most common neurological manifestation in Systemic Lupus Erythematosus (SLE). It affects a significant number of patients and includes a variety of symptoms such as memory problems, difficulty concentrating, and processing speed issues. Cognitive dysfunction in SLE is often referred to as lupus-associated neuropsychiatric syndrome or lupus fog, and it can range from mild to severe. It is considered one of the most frequent manifestations of neuropsychiatric involvement in SLE, affecting up to 50-70% of SLE patients in some studies. Why the Other Options Are Incorrect: A) Myelitis: While myelitis (inflammation of the spinal cord) can occur in SLE, it is relatively rare compared to other neurological manifestations. Myelitis in SLE typically presents with motor or sensory deficits and can be associated with long-term disability, but it is not as common as cognitive impairment. B) Neuropathy: Neuropathy, specifically peripheral neuropathy, can also occur in SLE, but it is less common than cognitive impairment. Neuropathy in SLE often presents with numbness, tingling, or weakness in the extremities, and it may be associated with autoimmune mechanisms or related to vasculitis. While it is a known manifestation of SLE, it is not the most frequent. C) Convulsion: Convulsions (seizures) can occur in SLE and are a known neurological complication of the disease. However, seizures are less common than cognitive impairment, affecting about 20-30% of SLE patients. They are usually associated with active lupus nephritis or neuropsychiatric lupus, but overall, convulsions are not the most frequent neurological manifestation in SLE.",
      "correct_choice_id": 245922,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15504701698838948/15504701698838948.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15504701698838948/15504701698838948.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96086,
      "choices": [
        {
          "id": 245923,
          "text": "Hypertension"
        },
        {
          "id": 245924,
          "text": "Active nephritis"
        },
        {
          "id": 245925,
          "text": "High complement levels"
        },
        {
          "id": 245926,
          "text": "Presence of Anti-phospholipid antibody"
        }
      ],
      "text": "The following findings are associated with increased fetal loss during pregnancy in a SLE patient except:",
      "unique_key": "Q3222387",
      "question_audio": null,
      "question_video": null,
      "map_id": 34948935,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) High complement levels. High complement levels are typically not associated with increased fetal loss in patients with Systemic Lupus Erythematosus (SLE). In fact, low complement levels (specifically C3 and C4) are often seen during periods of disease activity and have been linked to increased risk of fetal loss and adverse pregnancy outcomes in SLE patients. Complement levels are typically lower during active disease, especially when there is lupus nephritis or anti-phospholipid syndrome present. Therefore, high complement levels would not be a significant risk factor for fetal loss and is the exception in this context. Why the Other Options Are Correct: A) Hypertension: Hypertension, particularly pre-eclampsia, is a well-known complication of pregnancy in patients with SLE. Hypertensive disorders during pregnancy are associated with increased risks of fetal loss, preterm birth, and growth restriction. High blood pressure can adversely affect placental blood flow, increasing the likelihood of fetal complications. Therefore, hypertension in SLE patients is a known risk factor for fetal loss. B) Active nephritis: Active nephritis, especially lupus nephritis, is associated with a significantly higher risk of fetal loss in SLE patients. Kidney involvement in lupus often reflects increased disease activity, and this can contribute to poor pregnancy outcomes. Patients with active nephritis may experience hypertension, proteinuria, and renal failure, all of which can compromise pregnancy and fetal health. D) Presence of Anti-phospholipid antibody: The presence of anti-phospholipid antibodies (aPL), particularly lupus anticoagulant, anticardiolipin antibodies, and anti-β2-glycoprotein I antibodies, is a known risk factor for fetal loss in SLE patients. These antibodies are associated with an increased risk of miscarriage, preterm labor, and stillbirth due to their effects on coagulation and the formation of clots in placental vessels. Anti-phospholipid syndrome is a key contributor to adverse pregnancy outcomes in SLE.",
      "correct_choice_id": 245925,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1085331698838967/1085331698838967.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1085331698838967/1085331698838967.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96087,
      "choices": [
        {
          "id": 245927,
          "text": "ANA"
        },
        {
          "id": 245928,
          "text": "Anti-dsDNA"
        },
        {
          "id": 245929,
          "text": "Anti-Smith"
        },
        {
          "id": 245930,
          "text": "Anti-Ro (SSA)"
        }
      ],
      "text": "A 32-year-old woman presented with fatigue for the past few months. She complains of multiple joint pains and hair fall. She has had several spontaneous abortions and is very concerned about her ability to have children. Past medical history of hypertension present. On examination BP-150/98 mmHg, alopecia of scalp, and oral ulcers present. Chest: clear, Cardiovascular: normal, Musculoskeletal: no joint deformity. You are suspecting SLE. Which is the most specific test?",
      "unique_key": "Q9162976",
      "question_audio": null,
      "question_video": null,
      "map_id": 34631959,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Anti-Smith. In the context of Systemic Lupus Erythematosus (SLE), the anti-Smith antibody (anti-Sm) is the most specific test for confirming the diagnosis. Anti-Smith antibodies target a specific protein in the cell nucleus and are found in a significant proportion of patients with SLE, but they are rarely present in other autoimmune diseases. Therefore, a positive anti-Sm test provides strong evidence for the diagnosis of SLE, even though it is not as commonly positive as ANA (Antinuclear Antibody). Why the Other Options Are Incorrect: A) ANA (Antinuclear Antibody): ANA is the most sensitive test for SLE, as it is positive in nearly all cases of the disease. However, ANA is not specific for SLE and can be positive in other autoimmune conditions, infections, and even in healthy individuals. While a positive ANA test is a good screening tool, it cannot definitively confirm the diagnosis of SLE, making it less specific compared to anti-Sm. B) Anti-dsDNA: Anti-dsDNA (double-stranded DNA) antibodies are highly specific for SLE and are a hallmark of the disease. While they are strongly associated with SLE, they are not as specific as anti-Sm because they can also be present in other conditions, particularly in cases of nephritis and active disease in SLE patients. However, they are still highly useful in confirming SLE, especially when monitoring disease activity, but anti-Smith remains more specific. D) Anti-Ro (SSA): Anti-Ro (SSA) antibodies are more commonly seen in patients with Sjogren's syndrome and neonatal lupus, though they can be present in SLE as well. However, they are not as specific to SLE as anti-Smith antibodies. A positive anti-Ro test can be found in various conditions, so it does not provide the same level of specificity for SLE diagnosis as anti-Sm.",
      "correct_choice_id": 245929,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62638261698840169/62638261698840169.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/62638261698840169/62638261698840169.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96088,
      "choices": [
        {
          "id": 245931,
          "text": "Increasing ANA"
        },
        {
          "id": 245932,
          "text": "Decreasing complement level, increased dsDNA"
        },
        {
          "id": 245933,
          "text": "Increasing anti-Sm"
        },
        {
          "id": 245934,
          "text": "Anti-Ro Ab"
        }
      ],
      "text": "In previous question you ordered investigations in view of suspicion of autoimmune disease. Reports are as follows- Urine Analysis: proteinuria 300 (3+), red blood cells (RBCs) and RBC casts present, ANA: positive at 1:160, dsDNA: positive, CBC: WBC 12,400/?L (elevated); hematocrit 32%; MCV 86 fL; platelets 156,000/?L, Blood Urea- 60 mg/dL (elevated); creatinine 2.4 mg/dL. Which test is used to determine that increased renal disease activity is present?",
      "unique_key": "Q4244404",
      "question_audio": null,
      "question_video": null,
      "map_id": 34881473,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Decreasing complement level, increased dsDNA. In SLE, renal involvement is a significant complication, and it is essential to monitor renal disease activity. Complement levels (C3, C4) are often decreased during active lupus nephritis because complement proteins are consumed during immune complex deposition in the kidneys. Additionally, an increase in anti-dsDNA levels correlates with disease flare-ups, particularly in lupus nephritis. Thus, decreasing complement levels and increasing dsDNA levels are indicative of increased renal disease activity in SLE, specifically lupus nephritis. Why the Other Options Are Incorrect: A) Increasing ANA: While ANA is positive in nearly all patients with SLE, its levels do not correlate well with disease activity, especially renal activity. ANA is more of a screening test and is not specific for monitoring renal disease activity. It tends to remain positive even when the disease is well-controlled. Therefore, ANA levels are not a reliable marker for determining renal disease activity in SLE. C) Increasing anti-Sm: Anti-Smith (anti-Sm) antibodies are highly specific for SLE, but their levels do not correlate directly with disease activity, especially in terms of renal involvement. An increase in anti-Sm may confirm the diagnosis of SLE but does not serve as a marker for renal disease activity. Therefore, anti-Sm is not useful for monitoring renal disease progression in SLE. D) Anti-Ro Ab: Anti-Ro (SSA) antibodies are associated more with Sjogren's syndrome and neonatal lupus than with renal disease in SLE. While anti-Ro can be present in SLE, it is not specific for renal disease activity. Additionally, its levels are not closely related to lupus nephritis. Therefore, anti-Ro antibodies are not used to assess renal activity in SLE.",
      "correct_choice_id": 245932,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/57633771698840211/57633771698840211.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/57633771698840211/57633771698840211.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96089,
      "choices": [
        {
          "id": 245935,
          "text": "Hydralazine"
        },
        {
          "id": 245936,
          "text": "Hydrochlorothiazide"
        },
        {
          "id": 245937,
          "text": "Ramipril"
        },
        {
          "id": 245938,
          "text": "Nifedipine"
        }
      ],
      "text": "A 35-year-old woman notices a red rash over her cheeks, and pain and swelling in both knees as well as several small joints in her hands. She has a history of hypertension and 2 months ago was started on a new medication to control her blood pressure. Her ANA and antihistone antibodies are positive.CVS and CNS examination are normal. Which of the following medications is most likely to cause her condition?",
      "unique_key": "Q6698894",
      "question_audio": null,
      "question_video": null,
      "map_id": 34913762,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Hydralazine. This patient is presenting with butterfly-shaped red rash on her cheeks, joint pain and swelling, and a positive ANA and antihistone antibodies, which strongly suggest drug-induced lupus erythematosus (DILE). Among the medications listed, hydralazine is most strongly associated with the development of DILE. Hydralazine is a medication used for hypertension and can induce lupus-like syndrome in susceptible individuals. The presence of antihistone antibodies and ANA positivity further supports the diagnosis of drug-induced lupus. The characteristic features of DILE, including skin rashes, joint pain, and positive lab findings, fit the clinical scenario in this patient. Why the Other Options Are Incorrect: B) Hydrochlorothiazide: While hydrochlorothiazide (a diuretic used for hypertension) can cause certain side effects like electrolyte imbalances and photosensitivity, it is not commonly associated with drug-induced lupus. There is limited evidence of hydrochlorothiazide being a significant cause of lupus-like symptoms compared to hydralazine, which is a well-established trigger for DILE. Therefore, it is an unlikely cause of this patient's condition. C) Ramipril: Ramipril, an angiotensin-converting enzyme (ACE) inhibitor, is commonly used in the treatment of hypertension and heart failure. ACE inhibitors like ramipril are generally well-tolerated and are not known to cause drug-induced lupus. While ACE inhibitors can cause angioedema and hyperkalemia, they do not typically cause the autoimmune reactions (such as positive ANA and antihistone antibodies) associated with lupus. Therefore, ramipril is an unlikely cause of this patient's symptoms. D) Nifedipine: Nifedipine is a calcium channel blocker often used to treat hypertension and angina. It is generally well tolerated, but like other calcium channel blockers, it can cause side effects like peripheral edema or headache. However, nifedipine is not associated with the development of drug-induced lupus or the autoimmune features (e.g., positive ANA, rash, joint pain) seen in this patient. Therefore, nifedipine is not the likely cause of her condition.",
      "correct_choice_id": 245935,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67565521698840292/67565521698840292.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67565521698840292/67565521698840292.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96090,
      "choices": [
        {
          "id": 245939,
          "text": "Vasculitis"
        },
        {
          "id": 245940,
          "text": "Microemboli"
        },
        {
          "id": 245941,
          "text": "Antibasement membrane antibodies"
        },
        {
          "id": 245942,
          "text": "Deposition of circulating immune complexes"
        }
      ],
      "text": "A 28-year-old woman presents with a red rash over her cheeks, and pain and swelling in both knees as well as several small joints in her hands. She notes that the rash is worse with sun exposure. Medical evaluation reveals oral ulceration, pallor is positive and malar rash present.BP-150/100 mmHg, chest is clear on auscultation, CVS-normal. On Lab tests-positive ANA, and 3+ proteinuria is detected. Which of the following is the most likely mechanism for the renal damage in this condition?",
      "unique_key": "Q8744029",
      "question_audio": null,
      "question_video": null,
      "map_id": 34075473,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Deposition of circulating immune complexes. This patient has a classic presentation of Systemic Lupus Erythematosus (SLE), including: Malar rash (butterfly-shaped rash over the cheeks), Joint pain and swelling (including knees and small joints of the hands), Oral ulcers, Pallor, suggesting anemia, Positive ANA, a hallmark of autoimmune diseases like SLE, Proteinuria, indicating kidney involvement. In SLE, the renal damage is primarily due to the deposition of immune complexes in the kidney, particularly in the glomeruli. These immune complexes are formed when autoantibodies (such as anti-dsDNA) bind to self-antigens, and the complexes deposit in the kidneys, leading to immune complex-mediated glomerulonephritis. This can result in proteinuria and other signs of renal damage such as hematuria and decreased kidney function. Why the Other Options Are Incorrect: A) Vasculitis: While vasculitis (inflammation of blood vessels) can be seen in autoimmune diseases like SLE, it is not the primary mechanism of renal damage in this case. In SLE-related renal damage, the primary process involves the deposition of immune complexes rather than direct inflammation of the blood vessels (vasculitis). Vasculitis may contribute to other organ involvement, but it is not the primary cause of the renal damage seen in SLE. B) Microemboli: Microemboli, which are small clots that obstruct blood vessels, can lead to organ damage, but they are not typically associated with SLE renal disease. The main renal pathology in SLE is immune complex deposition leading to glomerulonephritis, not the formation of emboli. C) Antibasement membrane antibodies: Antibasement membrane antibodies are associated with Goodpasture syndrome, a condition where the immune system attacks the type IV collagen in the basement membrane of the lungs and kidneys. While this condition can cause kidney damage, it is not typical of SLE, where the renal damage is caused by immune complex deposition, not direct antibody attack on the basement membrane.",
      "correct_choice_id": 245942,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2631201698840324/2631201698840324.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/2631201698840324/2631201698840324.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96091,
      "choices": [
        {
          "id": 245943,
          "text": "Periarteritis Nodosa"
        },
        {
          "id": 245944,
          "text": "SLE"
        },
        {
          "id": 245945,
          "text": "Scleroderma"
        },
        {
          "id": 245946,
          "text": "Osteoarthritis"
        }
      ],
      "text": "A 25-year-old is referred for assessment of a low white cell count. She has no past medical history and is not on any medications. Her only symptoms are of joint discomfort in her hands, and occasional sharp chest pains that change with breathing. On examination, there is inflammation of some MCP and DIP joints in both hands, and the rest of the examination is normal. Her WBC is 3500/mL and the lymphocytes are low (15%) and PMNs are normal. Which of the following is the most likely diagnosis?",
      "unique_key": "Q1642213",
      "question_audio": null,
      "question_video": null,
      "map_id": 34210021,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) SLE (Systemic Lupus Erythematosus). This patient presents with a combination of symptoms and lab findings that suggest SLE, a systemic autoimmune disorder that can affect multiple organ systems. The key findings include: Joint discomfort: Common in SLE, particularly affecting the small joints like the MCP (metacarpophalangeal) and DIP (distal interphalangeal) joints. Chest pain: Sharp, pleuritic chest pain is also a frequent symptom in SLE due to pleuritis or pericarditis. Low white cell count: Leukopenia is a common feature of SLE, often due to a decrease in lymphocytes and neutrophils. Lymphopenia: The fact that lymphocytes are low (15%) with a normal PMN (polymorphonuclear neutrophils) count is suggestive of an immune system imbalance commonly seen in SLE. The combination of joint involvement, pleuritic chest pain, and low WBC with lymphopenia is highly suggestive of SLE, a diagnosis that requires further confirmation with specific laboratory tests like ANA and anti-dsDNA antibodies. Why the Other Options Are Incorrect: A) Periarteritis Nodosa (PAN): PAN is a type of systemic vasculitis affecting medium-sized arteries. It typically presents with skin lesions, muscle weakness, and neuropathy but not the joint discomfort or pleuritic chest pain described here. PAN also tends to cause systemic symptoms like fever and weight loss, which are not reported in this patient. The lab findings of low WBC with a normal PMN count are not characteristic of PAN, which often presents with elevated inflammatory markers. C) Scleroderma: Scleroderma is another autoimmune disorder that can cause joint pain and discomfort. However, it typically involves skin thickening and Raynaud's phenomenon (vasospasm in fingers and toes) along with specific pulmonary or renal involvement. This patient's presentation does not suggest scleroderma, as there are no skin changes or vascular phenomena. The low WBC with lymphopenia seen in SLE is not a typical feature of scleroderma. D) Osteoarthritis: Osteoarthritis (OA) is primarily a degenerative joint disease and does not typically cause the systemic symptoms seen here. Osteoarthritis presents with joint pain, especially in weight-bearing joints, but it is usually non-inflammatory and does not lead to low white cell counts. The patient's pleuritic chest pain and the presence of joint inflammation involving both the MCP and DIP joints are not typical of OA.",
      "correct_choice_id": 245944,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/69220521698840433/69220521698840433.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/69220521698840433/69220521698840433.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96092,
      "choices": [
        {
          "id": 245947,
          "text": "Pericarditis"
        },
        {
          "id": 245948,
          "text": "Myocarditis"
        },
        {
          "id": 245949,
          "text": "Aortic Regurgitation"
        },
        {
          "id": 245950,
          "text": "Nonbacterial Endocarditis"
        }
      ],
      "text": "A 30-year-old woman develops a rash over her cheeks, nose, and ears. She also has pain and swelling in her wrists as well as several small joints in her hands. Medical evaluation reveals oral ulceration and 3+ proteinuria. There is malar rash, pallor positive, chest-clear on auscultation. Her ANA and anti-DS DNA are positive. You made a clinical diagnosis of SLE. Which of the following is the most likely cardiac manifestation of her disease?",
      "unique_key": "Q7063206",
      "question_audio": null,
      "question_video": null,
      "map_id": 34653891,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Pericarditis. This 30-year-old woman has systemic lupus erythematosus (SLE), which is a chronic autoimmune disease that can affect multiple organ systems. Cardiac involvement is common in SLE, and one of the most common manifestations is pericarditis. Pericarditis is characterized by inflammation of the pericardial sac surrounding the heart, and it is the most common cardiac manifestation in SLE. It typically presents with chest pain that worsens with inspiration or coughing, and the pain may be relieved by sitting up or leaning forward. The patient may also develop a pericardial friction rub on auscultation. Pericarditis can lead to complications such as pericardial effusion or even cardiac tamponade in severe cases. The ANA and anti-DS DNA antibodies, which are positive in this patient, support the diagnosis of SLE and are associated with a higher risk of cardiac involvement, particularly pericarditis. Why the Other Options Are Incorrect: B) Myocarditis: Myocarditis, or inflammation of the heart muscle, is less common than pericarditis in SLE, but it can occur. It may lead to heart failure or arrhythmias, but it is a rarer cardiac manifestation compared to pericarditis. Myocarditis in SLE is often associated with other systemic manifestations of lupus, such as fatigue or shortness of breath. However, it is not as common or characteristic of lupus as pericarditis. C) Aortic Regurgitation: Aortic regurgitation (AR) is not typically a primary manifestation of SLE. While it can occur due to lupus-related valve disease, it is much less common than pericarditis. AR in lupus may be associated with Libman-Sacks endocarditis, a form of nonbacterial endocarditis (discussed below), but this is rarer compared to the more frequent development of pericarditis in lupus patients. D) Nonbacterial Endocarditis: Nonbacterial endocarditis, also known as Libman-Sacks endocarditis, is a form of valve disease associated with SLE. It involves the formation of sterile thrombi or vegetations on heart valves, particularly the mitral and aortic valves. While it can occur in SLE, it is not as common as pericarditis. This condition can lead to valvular insufficiency and may be associated with embolic phenomena, but it is less likely to be the primary cardiac manifestation in the patient described.",
      "correct_choice_id": 245947,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75015121698840508/75015121698840508.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75015121698840508/75015121698840508.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 96093,
      "choices": [
        {
          "id": 245951,
          "text": "RA factor"
        },
        {
          "id": 245952,
          "text": "ANAs"
        },
        {
          "id": 245953,
          "text": "Anti-Smith"
        },
        {
          "id": 245954,
          "text": "Anti-Ro"
        }
      ],
      "text": "A 32-year-old woman develops a red rash over her cheeks, and pain and swelling in both knees as well as several small joints in her hands.She also complains of hair fall,oral ulceration and frothy urine for last one month. Medical evaluation reveals malar rash, oral ulceration and tender small joints of hand.Lab test reveals 3+ proteinuria with low Hb. Which of the following is the most sensitive test for the diagnosis of this condition?",
      "unique_key": "Q1294069",
      "question_audio": null,
      "question_video": null,
      "map_id": 34104748,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) ANAs (Antinuclear Antibodies). This patient's presentation is highly suggestive of Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease that commonly presents with a malar rash, oral ulceration, joint pain, proteinuria, and anemia—all of which are seen in this case. The most sensitive test for diagnosing SLE is the Antinuclear Antibodies (ANA) test. ANA is positive in 95% of patients with SLE, making it the most sensitive screening tool for this condition, even though it is not specific to lupus (it can be positive in other autoimmune disorders as well). A positive ANA test in a patient with characteristic clinical signs of lupus strongly supports the diagnosis. Why the Other Options Are Incorrect: A) RA factor: The Rheumatoid Factor (RA factor) is a test used to help diagnose Rheumatoid Arthritis (RA), not SLE. It is typically positive in RA but can also be elevated in other conditions, including SLE. However, it is not specific or sensitive enough for diagnosing lupus, where ANA is much more commonly used. C) Anti-Smith: Anti-Smith (anti-Sm) antibodies are specific for SLE but are not as sensitive as ANA. Only about 30-40% of patients with SLE will test positive for anti-Smith antibodies. While a positive anti-Smith test is highly specific for lupus, it is not helpful for screening or diagnosing lupus in a broader population. It is often used to confirm the diagnosis after ANA has been found positive. D) Anti-Ro: Anti-Ro (anti-SSA) antibodies are associated with Sjögren’s syndrome and lupus, but they are not specific to lupus and are not as sensitive as ANA. Anti-Ro antibodies can be found in both SLE and Sjögren's syndrome, but their presence alone is not sufficient for diagnosing SLE. They are more often used to evaluate for specific manifestations of lupus, such as neonatal lupus or photosensitive rashes.",
      "correct_choice_id": 245952,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/35862001698841237/35862001698841237.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/35862001698841237/35862001698841237.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}